Taxus Cardium Pharmaceuticals Group Inc (CRXM)

[RichDude]

Article - TAXUS /BAXTER, Myocardial Ischemia Key Players!


Myocardial Ischemia Therapeutic Development Pipeline Key Players and Drugs Review H1 2015 Research Report



DALLAS, March 26, 2015 /PRNewswire/ --
RnRMarketResearch.com adds "Myocardial Ischemia - Pipeline Review, H1 2015" therapeutic market research report provides an overview of the Myocardial Ischemia's therapeutic pipeline
The report "Myocardial Ischemia - Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Myocardial Ischemia. Myocardial ischemia occurs when the blood flow through one or more of the blood vessels that lead to heart is decreased. Myocardial ischemia may occur slowly as arteries become blocked over time, or it may occur quickly when an artery becomes blocked suddenly. Myocardial ischaemia is responsible for angina, unstable angina, and, less commonly, shortness of breath secondary to ischaemic left ventricular dysfunction (angina equivalent) as well as cardiac arrhythmias.
This report is complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Myocardial Ischemia and special features on late-stage and discontinued projects.
Companies discussed in this report include:
Baxter International Inc.
CoDa Therapeutics, Inc.
Lixte Biotechnology Holdings, Inc.
Miltenyi Biotec GmbH
Nyken BV
Opsona Therapeutics Ltd.
Taxus Cardium Pharmaceuticals Group Inc.
ViroMed Co., Ltd.
Drug Profiles discussed in this report include alferminogene tadenovec, AntimiR-199a, EP-80317, Gene Therapy for Ischemic Heart Failure, Humanin, LB-100, LB-102, MG-53, NYK-1112, OPN-305, Peptagon, PMC-6, Protein for Myocardial Infarction and Critical Limb Ischemia, Recombinant Peptide to Activate FPR2 for Ischemia Reperfusion Injury and Myocardial Ischaemia, Recombinant Protein to Inhibit CXCL for Cardiovascular and Immunology, Small Molecule to Inhibit Arginase-1 and Arginase-2 for Myocardial Ischemia and Ischemia Reperfusion Injury, Small Molecules to Activate Heat Shock Protein H11 Kinase for Myocardial Ischemia, Small Molecules to Antagonize TRPM7 for Myocardial Ischemia and Glaucoma, Small Molecules to Inhibit Mst1 for Myocardial Ischemia, Stem Cell Therapy for Cardiovascular Disease, VM-202. Order a Purchase copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=328262 . (This is a premium report priced at US$2000 for a single user License.)
Featured News & Press Releases cover by this report includes: Jan 27, 2015: Taxus Cardium Announces Scientific Presentation And Clinical Update On Phase 3 Angiogenic Gene Therapy At The 2015 Phacilitate 11th Annual Cell & Gene Therapy Forum; Sep 03, 2014: Taxus Cardium to Present at the Rodman & Renshaw 16th Annual Global Investment Conference in New York City; Aug 13, 2014: Taxus Cardium Announces Biological and Clinical Advances in Angiogenic Gene Therapy for Heart Disease in Journal of Cardiovascular Pharmacology; Jun 12, 2014: Cardium To Announce Interim Results Of Generx Angiogenic Gene Therapy Phase 3 Clinical Study At The 2014 BIO International Convention; Jan 27, 2014: Cardium Announces Strategic Focus On Advanced Regenerative Therapeutics Based On Generx Clinical Findings; May 02, 2013: Cardium Therapeutics Announces Publication Of Data On Generx In Journal Molecular Therapy; Nov 19, 2012: Cardium Therapeutics Announces Patent Award For Rights To Cardiovascular Gene Therapy For Treatment Of Heart Disease; Oct 25, 2012: Cytori Announces Japanese Approval For Clinical Studies Of Cardiovascular And Chronic Liver Disease Cell Therapy; May 18, 2012: New drug discovery collaborations with Queen Mary University of London launched; Mar 20, 2012: Cardium Therapeutics Initiates Generx Phase III Clinical Registration Study.
Reasons to buy
Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
Develop strategic initiatives by understanding the focus areas of leading companies
Identify and understand important and diverse types of therapeutics under development for Myocardial Ischemia
Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
Devise corrective measures for pipeline projects by understanding Myocardial Ischemia pipeline depth and focus of Indication therapeutics
Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Explore more reports on Therapeutics at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/therapeutics .
More reports on Therapeutics Market:
Alpha- Antitrypsin Deficiency - Pipeline Review, H1 2015
This report provides comprehensive information on the therapeutic development for AlphaAntitrypsin Deficiency, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. Companies discussed in this report include Applied Immune Technologies Ltd, Astellas Pharma Inc., Bristol-Myers Squibb Company, Celgene Corporation, iDD biotech SAS, Kyowa Hakko Kirin Co., Ltd., MediGene AG, Nippon Kayaku Co., Ltd., Pfizer Inc., Pharmacyclics, Inc., Sanofi, Stemline Therapeutics, Inc., Theravectys S.A., Tolero Pharmaceuticals, Inc. Complete report available at http://www.rnrmarketresearch.com/alpha-antitrypsin-deficiency-pipeline-review-h1-2015-market-report.html .
Peripheral T-Cell Lymphomas (PTCL) - Pipeline Review, H1 2015
This report provides comprehensive information on the therapeutic development for Peripheral T-Cell Lymphomas (PTCL). The report reviews key pipeline products under drug profile section which includes product description, MoA and R&D brief, licensing and collaboration details & other developmental activities. Companies discussed in this report include AB Science, Affimed Therapeutics AG, Bayer AG, Celgene Corporation, Eisai Co., Ltd., Incyte Corporation, Karyopharm Therapeutics, Inc., Kyowa Hakko Kirin Co., Ltd., Millennium Pharmaceuticals, Inc., Mundipharma International Limited, Onxeo SA, Sanofi, Solasia Pharma K.K., Spectrum Pharmaceuticals, Inc., TG Therapeutics, Inc. Complete report available at http://www.rnrmarketresearch.com/peripheral-t-cell-lymphomas-ptcl-pipeline-review-h1-2015-market-report.html .
About Us:
RnRMarketResearch.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 100+ leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports.
Contact:
Ritesh Tiwari
TX, Dallas North - Dominion Plaza,
17304, Preston Road,
Suite 800, Dallas 75252
Tel: [phone]
[e-mail]